• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗精神病药物与可能延长QT间期的药物联合使用。

Concomitant use of antipsychotics and drugs that may prolong the QT interval.

作者信息

Roe Catherine M, Odell Kevin W, Henderson Rochelle R

机构信息

Division of Biostatistics and Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

出版信息

J Clin Psychopharmacol. 2003 Apr;23(2):197-200. doi: 10.1097/00004714-200304000-00013.

DOI:10.1097/00004714-200304000-00013
PMID:12640222
Abstract

Concomitant use of drugs that prolong the QT interval is a risk factor for torsades de pointes, a ventricular arrhythmia associated with sudden death. This study compared the concomitant use of drugs that may prolong the QT interval ("other QT drugs") among two groups of patients: one that took antipsychotics that may prolong the QT interval (the QT antipsychotic group, n = 1,750) and one that used antipsychotics that do not result in QT prolongation (the non-QT antipsychotic group, n = 1,139). Data were pharmacy claim and eligibility information from January 1, 2000, through December 31, 2000, from a research database of a large pharmacy benefit manager. Concomitant use of antipsychotics and other QT drugs was examined for each participant over a 3- to 12-month follow-up period. Results showed that 51% of QT antipsychotic group members used other QT drugs concomitantly for at least 1 day in the follow-up period. Logistic regression indicated that there was no significant difference between the QT antipsychotic and non-QT antipsychotic groups with concomitant use of other QT drugs when potential confounders were controlled ( p = 0.6013). Although female sex is a risk factor for drug-induced torsades de pointes, women were more likely to concomitantly use other QT drugs than men in both the QT (56.2% vs. 43.2%; p < 0.001) and non-QT (53.1% vs. 43.0%;p < 0.001) antipsychotic groups. Findings suggest that the use of other QT drugs is not being minimized among patients taking QT antipsychotics.

摘要

联用可延长QT间期的药物是尖端扭转型室速的一个风险因素,尖端扭转型室速是一种与猝死相关的室性心律失常。本研究比较了两组患者联用可能延长QT间期的药物(“其他QT药物”)的情况:一组服用可能延长QT间期的抗精神病药物(QT抗精神病药物组,n = 1750),另一组使用不会导致QT间期延长的抗精神病药物(非QT抗精神病药物组,n = 1139)。数据来自一家大型药房福利管理机构的研究数据库,涵盖2000年1月1日至2000年12月31日的药房报销申请和资格信息。在3至12个月的随访期内,对每位参与者联用抗精神病药物和其他QT药物的情况进行了检查。结果显示,QT抗精神病药物组中有51%的成员在随访期内至少有1天联用了其他QT药物。逻辑回归分析表明,在控制潜在混杂因素后,QT抗精神病药物组和非QT抗精神病药物组联用其他QT药物的情况无显著差异(p = 0.6013)。虽然女性是药物诱导的尖端扭转型室速的一个风险因素,但在QT抗精神病药物组(56.2%对43.2%;p < 0.001)和非QT抗精神病药物组(53.1%对43.0%;p < 0.001)中,女性比男性更有可能联用其他QT药物。研究结果表明,在服用QT抗精神病药物的患者中,其他QT药物的使用并未降至最低限度。

相似文献

1
Concomitant use of antipsychotics and drugs that may prolong the QT interval.抗精神病药物与可能延长QT间期的药物联合使用。
J Clin Psychopharmacol. 2003 Apr;23(2):197-200. doi: 10.1097/00004714-200304000-00013.
2
[Antipsychotic drugs and cardiovascular safety: need for monitoring the QT interval].[抗精神病药物与心血管安全性:QT间期监测的必要性]
Presse Med. 2006 Apr;35(4 Pt 2):699-704. doi: 10.1016/s0755-4982(06)74665-6.
3
Antipsychotic drugs and QT interval prolongation.抗精神病药物与QT间期延长
Psychiatr Q. 2003 Fall;74(3):291-306. doi: 10.1023/a:1024122706337.
4
Schizophrenia, antipsychotic drugs, and cardiovascular disease.精神分裂症、抗精神病药物与心血管疾病
J Clin Psychiatry. 2005;66 Suppl 6:5-10.
5
Ziprasidone in the management of schizophrenia : the QT interval issue in context.齐拉西酮治疗精神分裂症:QT间期问题剖析
CNS Drugs. 2003;17(6):423-30. doi: 10.2165/00023210-200317060-00004.
6
Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.抗精神病药物相关的QTc间期延长、尖端扭转型室速和猝死。
Drugs. 2002;62(11):1649-71. doi: 10.2165/00003495-200262110-00006.
7
The relationship between atypical antipsychotics drugs, QT interval prolongation, and torsades de pointes: implications for clinical use.非典型抗精神病药物、QT 间期延长和尖端扭转型室性心动过速之间的关系:对临床应用的影响。
Expert Opin Drug Saf. 2020 May;19(5):559-564. doi: 10.1080/14740338.2020.1745184. Epub 2020 Apr 15.
8
[Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].[抗精神病药物与心血管安全性:当前关于QT间期延长和室性心律失常风险的研究]
Encephale. 2000 Nov-Dec;26(6):62-72.
9
Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.抗精神病药物:QTc间期延长、尖端扭转型室速和猝死。
Am J Psychiatry. 2001 Nov;158(11):1774-82. doi: 10.1176/appi.ajp.158.11.1774.
10
[Lengthening of QT interval by antipsychotic drugs].[抗精神病药物导致QT间期延长]
Nervenarzt. 2006 Mar;77(3):276, 278-80, 282-4 passim. doi: 10.1007/s00115-005-1966-x.

引用本文的文献

1
Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system.喹硫平相关的心脏不良事件:美国食品药品监督管理局不良事件报告系统的比例失调分析。
CNS Neurosci Ther. 2023 Sep;29(9):2705-2716. doi: 10.1111/cns.14215. Epub 2023 Apr 10.
2
Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients.QT间期延长药物的联合处方:一项对大量老年患者队列的分析
PLoS One. 2016 May 18;11(5):e0155649. doi: 10.1371/journal.pone.0155649. eCollection 2016.
3
Cardiologic side effects of psychotropic drugs.
精神药物的心脏毒性作用。
J Geriatr Cardiol. 2011 Dec;8(4):243-53. doi: 10.3724/SP.J.1263.2011.00243.
4
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.医院环境中尖端扭转型室速的预防:美国心脏协会和美国心脏病学基金会的科学声明
J Am Coll Cardiol. 2010 Mar 2;55(9):934-47. doi: 10.1016/j.jacc.2010.01.001.
5
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.医院环境中尖端扭转型室速的预防:美国心脏协会和美国心脏病学基金会的科学声明
Circulation. 2010 Mar 2;121(8):1047-60. doi: 10.1161/CIRCULATIONAHA.109.192704. Epub 2010 Feb 8.
6
[Differences between men and women in side effects of second-generation antipsychotics].[第二代抗精神病药物副作用的性别差异]
Nervenarzt. 2007 Jan;78(1):45-52. doi: 10.1007/s00115-006-2112-0.
7
Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?第二代抗精神病药物:药代动力学和不良反应特征方面是否存在性别差异的证据?
Drug Saf. 2006;29(7):587-98. doi: 10.2165/00002018-200629070-00004.
8
Pharmacogenetic issues in thorough QT trials.全面QT试验中的药物遗传学问题。
Mol Diagn Ther. 2006;10(3):153-62. doi: 10.1007/BF03256454.
9
Pharmacogenetics in drug regulation: promise, potential and pitfalls.药物监管中的药物遗传学:前景、潜力与陷阱
Philos Trans R Soc Lond B Biol Sci. 2005 Aug 29;360(1460):1617-38. doi: 10.1098/rstb.2005.1693.
10
Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).老年人的药物研发与使用:探寻合适的剂量及给药方案(第一部分和第二部分)
Br J Clin Pharmacol. 2004 Nov;58(5):452-69. doi: 10.1111/j.1365-2125.2004.02228.x.